Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Affymax, Inc.
NEW YORK, Feb. 25, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Affymax, Inc. ("Affymax" or the "Company") (Nasdaq: AFFY). The investigation focuses on whether the Company and its executives violated federal securities laws.
On February 25, 2013, shares of Affymax plummeted over 80% in early morning trading after the company with Japanese pharmaceutical company Takeda, announced late Saturday a voluntary recall of anemia drug, Omontys, after a small percentage of patients experienced serious initial side effects, leading to a handful of patient deaths. The F.D.A. said in a news release on Sunday that it had received 19 reports of anaphylaxis, a severe allergic reaction, and that three of the patients had died, while others required prompt medical intervention or hospitalization.
If you are aware of any facts relating to this investigation, or purchased shares of Affymax, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC